One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Exercise over analgesics for osteoarthritis in the UK
doi : 10.1016/S2665-9913(22)00133-3
Volume 4, Issue 6, June 2022, Page e375
Combination therapies in rheumatoid arthritis—choose your partner carefully
Andrea Rubbert-Roth a
Early-stage Dupuytren's disease treatment; a promising next step?
doi : 10.1016/S2665-9913(22)00128-X
Volume 4, Issue 6, June 2022, Pages e377-e378
Immunosuppression and SARS-CoV-2 breakthrough infections
doi : 10.1016/S2665-9913(22)00127-8
Volume 4, Issue 6, June 2022, Pages e379-e380
Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
doi : 10.1016/S2665-9913(22)00109-6
Volume 4, Issue 6, June 2022, Pages e380-e382
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
doi : 10.1016/S2665-9913(22)00065-0
Volume 4, Issue 6, June 2022, Pages e382-e384
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
doi : 10.1016/S2665-9913(22)00069-8
Volume 4, Issue 6, June 2022, Pages e384-e387
Sulfasalazine: a risk factor for severe COVID-19?
doi : 10.1016/S2665-9913(22)00067-4
Volume 4, Issue 6, June 2022, Pages e388-e389
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
doi : 10.1016/S2665-9913(22)00101-1
Volume 4, Issue 6, June 2022, Pages e390-e391
Correction to Lancet Rheumatol 2022; 4: e262–73
doi : 10.1016/S2665-9913(22)00126-6
Volume 4, Issue 6, June 2022, Page e392
Fabian Proft: family, equity, and the future of rheumatology
doi : 10.1016/S2665-9913(22)00132-1
Volume 4, Issue 6, June 2022, Page e394
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
Prof Roy Fleischmann MD a, Alan Friedman MD b, Edit Drescher MD c, Atul Singhal MD d, Gregorio Cortes-Maisonet MD e, Thao Doan MD b, Wenjing Lu PhD b, Zailong Wang PhD b, Ahmed Nader PhD b, William Housley PhD b, Prof Stanley Cohen MD a, Prof Peter C Taylor PhD f, Ricardo Blanco MD g
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
doi : 10.1016/S2665-9913(22)00093-5
Volume 4, Issue 6, June 2022, Pages e407-e416
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
doi : 10.1016/S2665-9913(22)00102-3
Volume 4, Issue 6, June 2022, Pages e417-e429
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
doi : 10.1016/S2665-9913(22)00096-0
Volume 4, Issue 6, June 2022, Pages e430-e440
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
doi : 10.1016/S2665-9913(22)00107-2
Volume 4, Issue 6, June 2022, Pages e441-e449
Adolescent sarcoidosis mimicking malignant lymphoma
doi : 10.1016/S2665-9913(21)00210-1
Volume 4, Issue 6, June 2022, Page e450
